Dolphin
Senior Member (Voting Rights)
NCNED Facebook page:
www.facebook.com
/
NCNED is launching its first Double Blind 12 week Clinical Trial to investigate the effects of low dose naltrexone (LDN) in individuals with ME/CFS commencing in late March 2026.
We are currently seeking volunteers diagnosed by the CCC/ICC located in .
:
-Aged 18–65 years
-BMI between 18.5 and 29.9
-Not currently pregnant or breastfeeding
-Not taking routine medications that may interfere with naltrexone, such as opioids
Participants will receive LDN at doses of 3–6 mg/day for 12 weeks. The trial will evaluate:
-Ion channel function
-Brain MRI imaging (participants must be able to travel to Brisbane for MRI appointments)
-Quality of life and symptom assessments, including cognitive function, sleep, fatigue and body pain
The study aims to assess the effect of LDN on key biological markers and patient-reported symptoms, helping advance understanding of potential treatments for ME/CFS.
:
To register your interest or request further information, please email: ncned@griffith.edu.au
: At the end of 2026 NCNED will commence this Double Blind Clinical Trial in Victoria that will continue into 2027.
Best wishes,
Sonya and the NCNED team
NCNED would like to express our gratitude and appreciation to all the volunteers, Support Groups and the following Organizations:
• The Stafford Fox Medical Research Foundation
• National Health and Medical Research Council
• MERUK
• Dr John Hamwood
• The McCusker Charitable Foundation
• Mr Adrian Flack
• Talei Stewart
• The Alison Hunter Memorial Foundation
• The Buxton Foundation
• The Henty Community
• The Blake Beckett Foundation
• Change for ME Charity
• QLD ME/CFS/FM Support Association
• WA ME/CFS and Lyme Association
• Fibromyalgia ME/CFS Gold Coast Support Group Inc
• Tweed ME/CFS/FM Lyme Support Group
• ME/CFS South Australia Inc
• ME/CFS & FM Association NSW Inc
• ME/CFS Australia Ltd
• National Advocacy Advisory Council for ME/CFS
National Centre for Neuroimmunology and Emerging Diseases - NCNED
/ NCNED is launching its first Double Blind 12 week Clinical Trial to investigate the effects of low dose naltrexone (LDN) in...
www.facebook.com
/
NCNED is launching its first Double Blind 12 week Clinical Trial to investigate the effects of low dose naltrexone (LDN) in individuals with ME/CFS commencing in late March 2026.
We are currently seeking volunteers diagnosed by the CCC/ICC located in .
:
-Aged 18–65 years
-BMI between 18.5 and 29.9
-Not currently pregnant or breastfeeding
-Not taking routine medications that may interfere with naltrexone, such as opioids
Participants will receive LDN at doses of 3–6 mg/day for 12 weeks. The trial will evaluate:
-Ion channel function
-Brain MRI imaging (participants must be able to travel to Brisbane for MRI appointments)
-Quality of life and symptom assessments, including cognitive function, sleep, fatigue and body pain
The study aims to assess the effect of LDN on key biological markers and patient-reported symptoms, helping advance understanding of potential treatments for ME/CFS.
:
To register your interest or request further information, please email: ncned@griffith.edu.au
: At the end of 2026 NCNED will commence this Double Blind Clinical Trial in Victoria that will continue into 2027.
Best wishes,
Sonya and the NCNED team
NCNED would like to express our gratitude and appreciation to all the volunteers, Support Groups and the following Organizations:
• The Stafford Fox Medical Research Foundation
• National Health and Medical Research Council
• MERUK
• Dr John Hamwood
• The McCusker Charitable Foundation
• Mr Adrian Flack
• Talei Stewart
• The Alison Hunter Memorial Foundation
• The Buxton Foundation
• The Henty Community
• The Blake Beckett Foundation
• Change for ME Charity
• QLD ME/CFS/FM Support Association
• WA ME/CFS and Lyme Association
• Fibromyalgia ME/CFS Gold Coast Support Group Inc
• Tweed ME/CFS/FM Lyme Support Group
• ME/CFS South Australia Inc
• ME/CFS & FM Association NSW Inc
• ME/CFS Australia Ltd
• National Advocacy Advisory Council for ME/CFS
